Tg Therapeutics (TGTX) Short term Debt (2010 - 2021)
Tg Therapeutics (TGTX) recorded quarterly Short term Debt of $975000.0 in Q4 2021, down 93.91% quarter-over-quarter from $16.0 million in Q3 2021, and down 95.6% on a YoY basis from $22.2 million in Q4 2020.
Tg Therapeutics (TGTX) Short term Debt (2010 - 2021) Analysis & Trends
Tg Therapeutics' Short term Debt history runs 4 years deep, the most recent figure standing at $975000.0 for Q4 2021.
- In Q4 2021, Short term Debt fell 95.6% year-over-year to $975000.0; the TTM figure through Dec 2021 stood at $975000.0 (down 95.6% YoY), while the FY2021 annual figure was $975000.0, down 95.6% from the prior year.
- Short term Debt was $975000.0 for Q4 2021 at Tg Therapeutics, down from $16.0 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $30.1 million in Q1 2021 to a low of $975000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Tg Therapeutics | 7.71 Bn | 7.06 Bn | 171.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 975,000.00 |
| Sep 30, 2021 | 16.00 Mn |
| Jun 30, 2021 | 23.16 Mn |
| Mar 31, 2021 | 30.13 Mn |
| Dec 31, 2020 | 22.18 Mn |
| Sep 30, 2020 | 14.59 Mn |
| Jun 30, 2020 | 7.20 Mn |
| Sep 30, 2011 | 538,830.00 |
| Jun 30, 2011 | 2.64 Mn |
| Dec 31, 2010 | 534,846.00 |